ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
65 announcements
Alembic Pharmaceuticals Limited has incorporated a subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The company holds a 99.99% stake in the new entity, which has a share capital of 12 million Philippine Pesos. The subsidiary will explore business opportunities to promote and distribute pharmaceutical products in the region.
Alembic Pharmaceuticals Limited received USFDA final approval for Methotrexate Injection USP in multi-dose and single-dose vials. The drug is indicated for neoplastic diseases, rheumatoid arthritis, and severe psoriasis. This marks the company's 236th ANDA approval, strengthening its generic injectable portfolio in the US market.
Alembic Pharmaceuticals Limited certified the full utilization of ₹400 Crore raised through Commercial Papers issued between January and March 2026. The funds were deployed for purposes disclosed in the respective documents, ensuring compliance with SEBI listing conditions.
Alembic Pharmaceuticals received USFDA final approval for Dapagliflozin Tablets (5 mg and 10 mg), used for type 2 diabetes and heart failure. The product addresses a US$ 10,487 million (₹9,752.91 Crore) market. As a Paragraph IV applicant, Alembic is eligible for 180 days of shared generic exclusivity, marking its 217th final ANDA approval.
Alembic Pharmaceuticals Ltd submitted an annual compliance certificate from a Chartered Accountant for the CRA Family Trust. The certificate confirms compliance with the SEBI Exemption Order dated September 30, 2020, for the financial year ended March 31, 2026.